<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Skoda RC</dc:creator>
  <dc:date>2009</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Major progress in understanding the pathogenesis in patients with thrombocytosis has been made by identifying mutations in the key regulators of thrombopoietin: the thrombopoietin receptor MPL and JAK2. Together, these mutations can be found in 50% to 60% of patients with essential thrombocythemia or primary myelofibrosis and in 10% to 20% of hereditary thrombocytosis. A decrease in expression of the Mpl protein can cause thrombocytosis even in the absence of mutations in the coding sequence, due to a shift in the balance between stimulation of signaling in megakaryopoiesis and removal of thrombopoietin by receptor mediated internalization in platelets. When present in a heterozygous state the JAK2-V617F mutation preferentially stimulates megakaryopoiesis and in most cases manifests as essential thrombocythemia (ET), whereas homozygous JAK2-V617F reduces megakaryopoiesis in favor of increased erythropoiesis, resulting in polycythemia vera and/or myelofibrosis. In 30% to 40% of patients with ET or primary myelofibrosis (PMF) and in 80% to 90% of pedigrees with hereditary thrombocytosis the disease-causing gene remains unknown. Ongoing genetic and genomic screens have identified genes that, when mutated, can cause thrombocytosis in mouse models. A more complete picture of the pathways that regulate megakaryopoisis and platelet production will be important for finding new ways of controlling platelet production in patients with thrombocytosis.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/228062</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1182/asheducation-2009.1.159</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/20008195</dc:relation>
  <dc:source>Hematology. American Society of Hematology. Education Program. - 2009</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Adult</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Amino Acid Substitution</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Animals</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Disease Models, Animal</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Janus Kinase 2</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Mice</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Mice, Inbred C57BL</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Mutation</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Mutation, Missense</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Polycythemia Vera</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Primary Myelofibrosis</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Receptors, Thrombopoietin</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Recombinant Fusion Proteins</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">STAT Transcription Factors</dc:subject>
  <dc:subject xmlns:ns16="xml" ns16:lang="en">Thrombocythemia, Essential</dc:subject>
  <dc:subject xmlns:ns17="xml" ns17:lang="en">Thrombocytosis</dc:subject>
  <dc:subject xmlns:ns18="xml" ns18:lang="en">Thrombopoiesis</dc:subject>
  <dc:subject xmlns:ns19="xml" ns19:lang="en">Thrombopoietin</dc:subject>
  <dc:subject xmlns:ns20="xml" ns20:lang="en">Transduction, Genetic</dc:subject>
  <dc:title xmlns:ns21="xml" ns21:lang="en">Thrombocytosis.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
